Trial names used in this review ADAPT: Alzheimer's Disease Anti-inflammatory Prevention Trial APC: Adenoma Prevention with Celecoxib APPROVe: Adenomatous Polyp Prevention on Vioxx
CLASS: Celecoxib Long-term Arthritis Safety Study MEDAL programme: Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme PreSAP: Prevention of colorectal Spontaneous Adenomatous Polyps TARGET: Therapeutic Arthritis Research and Gastrointestinal Event Trial VIGOR: Vioxx Gastrointestinal Outcomes Research Table II.
Merck voluntarily withdrew rofecoxib from the market in September on the basis of findings in the Adenomatous Polyp Prevention on Vioxx
(APPROVe) trial, which found a relative risk of 1.96 for thrombotic events in rofecoxib-treated patients, compared with those given placebo.
The APPROVe (Adenomatous Polyp Prevention on Vioxx
) study enrolled about 2,600 patients with a history of colorectal adenomas, at risk for recurrent polyps, and aged 40-94 years (average age 60 years).